SCK CEN

EANM’26 may be over, but the next steps in radiopharmaceutical R&D are already taking shape. Looking for specialised expertise, advanced infrastructure or the right collaboration to move your research forward? SCK CEN can support different stages of your R&D through different partnership pathways. From preclinical research to irradiation and radioisotope production (e.g. Lu-177 and Tb-161). Let’s continue the conversation and explore where SCK CEN could fit into your R&D journey. 👉 Get in touch with our team.

Exploring a new radioisotope? Validating a promising radiopharmaceutical candidate? Preparing for clinical studies or scaling up for commercial supply? Every stage of development comes with different irradiation needs. Are you looking for irradiation capacity that fits your project? ⚛ BR2 combines specialised nuclear infrastructure with decades of scientific and technical expertise. This enables SCK CEN to support organisations with a range of irradiation needs. Our collaboration can include the irradiation of targets for: ✔ Large-scale, commercial supply ✔ Research, development and trials for new radioisotopes Curious what BR2 could mean for your organisation? Explore the possibilities at EANM’26. 📅 Meet SCK CEN at EANM’26, October 17–21 📍 Booth 404 | Vienna

Every R&D journey calls for a different kind of partnership. 🔬 Some projects require specialised scientific expertise. Others need access to technology platforms or infrastructure. And sometimes, joining forces through co-development is the right way forward. At SCK CEN, collaboration can take different forms depending on your R&D needs: ✔ Knowledge-based support ✔ Technology platform access ✔ Co-development ✔ Isotope supply ✔ Access to an RLT/CDMO network Where are you on your radiopharmaceutical development journey from drug discovery to (pre)clinical studies? And how can we support you? Together we can identify the pathway that fits your R&D. Find your pathway at EANM’26. 📅 Meet SCK CEN at EANM’26, October 17–21 📍 Booth 404 | Vienna

What does your radiopharmaceutical R&D need to move forward? 🔬 You don’t need to have every capability in-house. A partner can complement your team where specialised scientific and technical expertise, technology or infrastructure is needed. Depending on your R&D trajectory, SCK CEN can support you through with: ✔ Knowledge-based guidance ✔ Technology platform access ✔ Preclinical research capabilities ✔ Isotope supply ✔ Co-development ✔ Access to an RLT/CDMO network From drug discovery to (pre)clinical studies, every development stage brings different questions and challenges. Whether you are looking for expertise, infrastructure or a broader collaboration, let’s identify the partnership pathway that best fits your ambitions. Find your pathway at EANM’26. 📅 Meet SCK CEN at EANM’26, October 17–21 📍 Booth 404 | Vienna

Looking for specialised irradiation capabilities? ☢️ At the heart of SCK CEN’s nuclear infrastructure is BR2, one of the world’s most powerful research reactors. Combined with decades of nuclear expertise, BR2 enables SCK CEN to support organisations looking for specialised irradiation capabilities: from commercial irradiations to research into new irradiation possibilities. A unique infrastructure backed by the expertise to explore what’s possible. 📅 Discover SCK CEN at EANM’26, October 17–21 📍 Booth 404 | Vienna

Radiopharmaceutical R&D needs more than a promising idea. 🔬 It takes specialised scientific expertise, advanced infrastructure and the right partners to move innovation forward. At SCK CEN, these elements come together in one unique R&D environment. From preclinical research and radiochemistry to nuclear expertise and specialised infrastructure; our capabilities create opportunities for collaboration across radiopharmaceutical R&D. And because every R&D journey is different, so is every partnership. Find your pathway to partnership. 📅 Meet SCK CEN at EANM’26, October 17–21 📍 Booth 404 | Vienna